Open AccessBopindolol: Pharmacological Basis and Clinical Implications
Author(s) -
Nagatomo Takafumi,
Hosohata Yoshiaki,
Ohnuki Toshio,
Nakamura Takashi,
Hattori Kaoru,
Suzuki Jun,
Ishiguro Masaji
Publication year - 2001
Publication title -
cardiovascular drug reviews
Language(s) - English
Resource type - Journals
eISSN - 1527-3466
pISSN - 0897-5957
DOI - 10.1111/j.1527-3466.2001.tb00180.x
Subject(s) - pindolol , beta (programming language) , pharmacology , molecular pharmacology , adrenergic beta antagonists , medicine , antagonist , biological activity , receptor , chemistry , endocrinology , propranolol , biochemistry , in vitro , computer science , programming language
Bopindolol, a non‐selective antagonist of β 1 ‐ and β 2 ‐adrenoceptors (ARs), has been found by pharmacological, molecular biological techniques and molecular modeling to have several unique properties. Bopindolol produces sustained blockade of β 1 ‐ and β 2 ‐ARs, has intrinsic sympathomimetic as well as membrane stabilizing actions, inhibits renin secretion, and interacts with 5‐HT receptors. Also, our recent molecular modeling studies identified possible interaction sites between bopindolol and beta‐AR subtypes. The reviewed studies support our findings that bopindolol is non‐selective for β 1 ‐ and β 2 ‐ARs, has low affinity for β 3 ‐AR subtype and has pharmacological properties that are likely to be beneficial in the treatment of cardiovascular diseases.